SCHEMBL688771

SCHEMBL688771

CCOC(=O)C(F)(F)C(N)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.39
ALDH1A1 P00352 2/20 0.37
MMP8 P22894 1/20 0.37
PKM P14618 3/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
LMNA P02545 2/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP4F2 P78329 2/20 0.35
CYP4A11 Q02928 2/20 0.35
THRB P10828 1/20 0.35
POLB P06746 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MGAM O43451 1/20 0.34
GAA P10253 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34
SOAT1 P35610 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11378341 0.83 MMP8 (0.41) ALOX15ALDH1A1MMP8PKMKDM4E
SCHEMBL1682735 0.83 CYP4F2 (0.41) ALOX15ALDH1A1MMP8PKMKDM4E
SCHEMBL954289 0.83 MMP8 (0.43) ALOX15ALDH1A1MMP8PKMKDM4E
SCHEMBL18681535 0.80 ALOX15 (0.37) ALOX15ALDH1A1MMP8PKMKDM4E
SCHEMBL13936374 0.79 ALDH1A1 (0.37) ALOX15ALDH1A1MMP8PKMKDM4E
SCHEMBL16492775 0.79 MMP8 (0.41) ALOX15ALDH1A1MMP8PKMKDM4E
SCHEMBL14504422 0.78 MMP8 (0.43) ALOX15ALDH1A1MMP8PKMKDM4E
SCHEMBL13539346 0.78 MMP8 (0.36) ALOX15ALDH1A1MMP8PKMKDM4E
SCHEMBL8599101 0.78 PKM (0.39) ALOX15ALDH1A1MMP8PKMKDM4E
SCHEMBL13815187 0.77 ALOX15 (0.34) ALOX15ALDH1A1MMP8PKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116249697-A Bicycloheptane pyrrolidine orexin receptor agonists 默沙东有限责任公司 2023-06-09 CN disclosed
EP-1904438-B1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS NOVO NORDISK AS (DK) 2012-02-29 EP disclosed
US-7999114-B2 Dicycloalkylcarbamoyl ureas as glucokinase activators NOVO NORDISK A/S (DK) 2011-08-16 US disclosed
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators NOVO NORDISK A/S (DK) 2008-12-25 US disclosed
EP-1904438-A1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS Novo Nordisk A/S (DK) 2008-04-02 EP disclosed
WO-2007006761-A1 DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319028-A1 Dicycloalkylcarbamoyl Ureas As Glucokinase Activators GCK, HK1, GCKR ALOX15 3362/4885ALDH1A1 2374/4885MMP8 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.